: Azole antifungal resistance has emerged as a significant problem in the management of infections caused by a number of fungal species including Candida. This problem has had a significant impact in immune-compromised patient populations, particularly those suffering from AIDS. While the use of highly active antiretroviral therapy (HAART) has reduced the frequency of OPC among AIDS patients in the United States, limited access to such therapy in underdeveloped countries, poor compliance, and toxicity associated with HAART will likely contribute to an increase in this problem among AIDS patients world-wide. Understanding the molecular basis of azole resistance will facilitate the development of therapeutic strategies to circumvent this problem and improve the utility of the azole class of antifungal agents.
The aim of this proposal is to identify and characterize novel molecular mechanisms of azole antifungal resistance in Candida albicans. The central hypothesis behind this proposal is that genes in addition to CDR1, CDR2, MDR1, ERG11 and PDR16 are required for the stepwise acquisition of azole antifungal resistance in C. albicans. We will use an integrated functional genomic and proteomic approach to characterize and compare the gene expression and proteomic profiles of serial isolates within and between multiple matched sets of azole-susceptible and -resistant isolates of C. albicans. These studies will identify genes and gene products that are associated with the azole resistance phenotype. They will also identify genes and gene products that are coordinately regulated with known resistance mechanisms and hence lend insight into the transcriptional regulation of these mechanisms. We will also screen azole resistant isolates for genes required for this phenotype using an antisense cDNA library. Targeted gene disruption and over-expression will be used to assess the role of candidate resistance genes in this process. These mutants will then be examined for changes in in vitro azole susceptibility. Additional studies will examine the nucleotide sequences of key genes for point mutations that may play a role in this process. These studies will further elucidate the molecular basis for azole antifungal resistance and will identify novel targets for future work towards the development of compounds that will both abrogate resistance and enhance the utility of the azole class of antifungal agents.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI058145-03
Application #
7235410
Study Section
Special Emphasis Panel (ZRG1-DDR (01))
Program Officer
Duncan, Rory A
Project Start
2005-06-01
Project End
2009-05-21
Budget Start
2007-06-01
Budget End
2009-05-21
Support Year
3
Fiscal Year
2007
Total Cost
$321,661
Indirect Cost
Name
University of Tennessee Health Science Center
Department
Other Health Professions
Type
Schools of Pharmacy
DUNS #
941884009
City
Memphis
State
TN
Country
United States
Zip Code
38163
Whaley, Sarah G; Zhang, Qing; Caudle, Kelly E et al. (2018) Relative Contribution of the ABC Transporters Cdr1, Pdh1, and Snq2 to Azole Resistance in Candida glabrata. Antimicrob Agents Chemother 62:
Luna-Tapia, Arturo; Willems, Hubertine M E; Parker, Josie E et al. (2018) Loss of Upc2p-Inducible ERG3 Transcription Is Sufficient To Confer Niche-Specific Azole Resistance without Compromising Candida albicans Pathogenicity. MBio 9:
Popp, Christina; Hampe, Irene A I; Hertlein, Tobias et al. (2017) Competitive Fitness of Fluconazole-Resistant Clinical Candida albicans Strains. Antimicrob Agents Chemother 61:
Butts, Arielle; Palmer, Glen E; Rogers, P David (2017) Antifungal adjuvants: Preserving and extending the antifungal arsenal. Virulence 8:198-210
Rybak, Jeffrey M; Dickens, C Michael; Parker, Josie E et al. (2017) Loss of C-5 Sterol Desaturase Activity Results in Increased Resistance to Azole and Echinocandin Antifungals in a Clinical Isolate of Candida parapsilosis. Antimicrob Agents Chemother 61:
Peters, Brian M; Luna-Tapia, Arturo; Tournu, Hélène et al. (2017) An Azole-Tolerant Endosomal Trafficking Mutant of Candida albicans Is Susceptible to Azole Treatment in a Mouse Model of Vaginal Candidiasis. Antimicrob Agents Chemother 61:
Whaley, Sarah G; Tsao, Sarah; Weber, Sandra et al. (2016) The RTA3 Gene, Encoding a Putative Lipid Translocase, Influences the Susceptibility of Candida albicans to Fluconazole. Antimicrob Agents Chemother 60:6060-6
Whaley, Sarah G; Berkow, Elizabeth L; Rybak, Jeffrey M et al. (2016) Azole Antifungal Resistance inCandida albicansand Emerging Non-albicans CandidaSpecies. Front Microbiol 7:2173
Berkow, Elizabeth L; Manigaba, Kayihura; Parker, Josie E et al. (2015) Multidrug Transporters and Alterations in Sterol Biosynthesis Contribute to Azole Antifungal Resistance in Candida parapsilosis. Antimicrob Agents Chemother 59:5942-50
Rybak, Jeffrey M; Marx, Kayleigh R; Nishimoto, Andrew T et al. (2015) Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent. Pharmacotherapy 35:1037-51

Showing the most recent 10 out of 34 publications